AR078228A1 - Inhibidores de cyp17 - Google Patents
Inhibidores de cyp17Info
- Publication number
- AR078228A1 AR078228A1 ARP100102237A ARP100102237A AR078228A1 AR 078228 A1 AR078228 A1 AR 078228A1 AR P100102237 A ARP100102237 A AR P100102237A AR P100102237 A ARP100102237 A AR P100102237A AR 078228 A1 AR078228 A1 AR 078228A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- phenyl
- substituted
- optionally substituted
- Prior art date
Links
- 229940124766 Cyp17 inhibitor Drugs 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 33
- 229910052736 halogen Inorganic materials 0.000 abstract 13
- 150000002367 halogens Chemical class 0.000 abstract 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 229920006395 saturated elastomer Polymers 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- QZFLXEYQSSOUKY-UHFFFAOYSA-N 1,3-bis(4-methylpyridin-2-yl)imidazolidin-2-one Chemical compound CC1=CC=NC(N2C(N(CC2)C=2N=CC=C(C)C=2)=O)=C1 QZFLXEYQSSOUKY-UHFFFAOYSA-N 0.000 abstract 1
- YYIWLLRVTGDCMM-UHFFFAOYSA-N 1,3-bis(6-chloropyridin-2-yl)-1,3-diazinan-2-one Chemical compound ClC1=CC=CC(N2C(N(CCC2)C=2N=C(Cl)C=CC=2)=O)=N1 YYIWLLRVTGDCMM-UHFFFAOYSA-N 0.000 abstract 1
- KLQQLINXJPIDFI-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-[6-(2-piperidin-1-ylethoxy)pyridin-3-yl]imidazolidin-2-one Chemical compound C1=C(Cl)C(Cl)=CC=C1N1C(=O)N(C=2C=NC(OCCN3CCCCC3)=CC=2)CC1 KLQQLINXJPIDFI-UHFFFAOYSA-N 0.000 abstract 1
- UXSYRPAHXAKPIO-UHFFFAOYSA-N 1-(3,5-dichloropyridin-2-yl)-3-phenyl-1,3-diazinan-2-one Chemical compound ClC1=CC(Cl)=CN=C1N1C(=O)N(C=2C=CC=CC=2)CCC1 UXSYRPAHXAKPIO-UHFFFAOYSA-N 0.000 abstract 1
- NYTAKBBVMIOYLC-UHFFFAOYSA-N 1-(6-chloro-1h-benzimidazol-2-yl)-3-phenylimidazolidin-2-one Chemical compound N=1C2=CC(Cl)=CC=C2NC=1N(C1=O)CCN1C1=CC=CC=C1 NYTAKBBVMIOYLC-UHFFFAOYSA-N 0.000 abstract 1
- UGVUZYHUHPXLRY-UHFFFAOYSA-N 2-(2-oxo-3-phenylimidazolidin-1-yl)-3h-benzimidazole-5-carbonitrile Chemical compound O=C1N(C=2NC3=CC=C(C=C3N=2)C#N)CCN1C1=CC=CC=C1 UGVUZYHUHPXLRY-UHFFFAOYSA-N 0.000 abstract 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 150000003222 pyridines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se ha encontrado que los compuestos de la presente son utiles como inhibidores de 17a-hidroxilasa/liasa-C17-20. Composiciones farmacéuticas y usos. Reivindicacion 1: Un compuesto de la formula (1) o (2), en donde: n es 1, 2, o 3; R53 es: (i) fenilo opcionalmente sustituido con 1 a 3 sustituyentes seleccionados a partir de halogeno, -CN, -OH, alquilo C1-6, alquilo C1-6 sustituido por halogeno, alcoxilo C1-6, -NH2, -NH-alquilo C1-4, -N-(alquilo C1-4)2, -NHC(O)-alquilo C1-4, -C(O)NH2, -C(O)-NH-alquilo C1-4, -C(O)-N-(alquilo C1-4)2, o un heterociclo de 5 a 6 miembros, (ii) bifenilo opcionalmente sustituido con 1 a 3 sustituyentes seleccionados a partir de alquilo C1-4 o halogeno, (iii) fenilo fusionado con un fenilo adicional, un heteroarilo de 5 a 6 miembros, un cicloalquilo de 5 a 6 miembros parcialmente o completamente saturado, o un heterociclo de 5 a 6 miembros parcialmente o completamente saturado, en donde el fenilo fusionado está opcionalmente sustituido con 1 a 4 sustituyentes, cada uno independientemente seleccionado a partir de halogeno, -CN, alquilo C1-6, alcoxilo C1-6, alquilo C1-4 sustituido por hidroxilo, alquilo C1-4 sustituido por halogeno, ciclopropilo, oxo, -NH2, -NH-alquilo C1-4, -N-(alquilo C1-4)2, -NHC(O)alquilo C1-4, o =N-OH, (iv) heteroarilo de 5 a 6 miembros opcionalmente sustituido con 1 a 3 sustituyentes seleccionados a partir de halogeno, -CN, -OH, alquilo C1-6, alquilo C1-6 sustituido por halogeno, alcoxilo C1-6, -NH2, -NH-alquilo C1-4, -N-(alquilo C1-4)2, -NHC(O)alquilo C1-4, -C(O)NH2, -C(O)-NH-alquilo C1-4, -C(O)-N-(alquilo C1-4)2, o un heterociclo de 5 a 6 miembros, (v) heteroarilo de 5 a 6 miembros fusionado con otro heteroarilo de 5 a 6 miembros, fenilo, cicloalquilo de 5 a 6 miembros parcialmente o completamente saturado, o un heterociclo de 5 a 6 miembros parcialmente o completamente saturado, en donde el heteroarilo fusionado está opcionalmente sustituido con 1 a 4 sustituyentes, cada uno independientemente seleccionado a partir de halogeno, -CN, alquilo C1-6, alcoxilo C1-6, alquilo C1-4 sustituido por hidroxilo, alquilo C1-4 sustituido por halogeno, ciclopropilo, oxo, -NH2, -NH-alquilo C1-4, -N-(alquilo C1-4)2, -NHC(O)-alquilo C1-4, o =N-OH; R54 es alquilo C1-4, alquilo C1-4 sustituido por halogeno, o -CH2OH, o dos R54 tomados junto con los átomos de carbono con los que están unidos, forman un anillo carbocíclico de 3 a 6 miembros completamente o parcialmente saturado, o dos R54 unidos a los átomos de carbono adyacentes tomados junto con los átomos de carbono con los que están unidos, forman un fenilo fusionado; p es 0, 1, 2, o 3; q es 0, 1 o 2; A es un heteroarilo de 5 a 10 miembros que contiene uno o más átomos de nitrogeno, en donde el heteroarilo está opcionalmente sustituido con 1 a 3 sustituyentes, cada uno independientemente seleccionado a partir de halogeno, -OH, -CN, alquilo C1-4, alquilo C1-4 sustituido por halogeno, alquilo C1-4 sustituido por hidroxilo, -(CH2)rO-alquilo C1-4, -(CH2)rCH(O-alquilo C1-4)2, -NH-alquilo C1-4, -(CH2)sNH-alquilo C1-4, -(CH2)rN-(alquilo C1-4)2, -(CH2)rNH-cicloalquilo C3-6, -NH2, -NHC(O)-alquilo C1-4, -C(O)NH2, -C(O)-NH-alquilo C1-4, -C(O)-N-(alquilo C1-4)2, o -C(O)-O-alquilo C1-4, en donde el alquilo C1-4, el -(CH2)rO-alquilo C1-4, y el -(CH2)sNH-alquilo C1-4 están opcionalmente sustituidos con un heterociclo o heteroarilo de 4 a 6 miembros parcialmente o completamente saturado que contiene de 1 a 3 heteroátomos, cada uno independientemente seleccionado a partir de O, S o N, en donde el heterociclo y el heteroarilo están opcionalmente sustituidos con 1 a 3 grupos alquilo C1-4; r es 0, 1 o 2; s es 1 o 2; o una sal farmacéuticamente aceptable del mismo; con la condicion de que: (i) cuando A es una piridina insustituida y R53 es fenilo, R53 no está insustituido o mono-sustituido con halogeno, CH3, NH2, -NHC(O)CH3, o CF3; (ii) A y R53 no son ambos un piridin-2-ilo insustituido; y (iii) el compuesto mencionado no es 1-(3,4-dicloro-fenil)-3-[6-(2-piperidin-1-il-etoxi)-piridin-3-il]-imidazolidin-2-ona, 1-(3,5-dicloro-piridin-2-il)-3-fenil-tetrahidro-pirimidin-2(1H)-ona, 1,3-bis-(6-cloro-piridin-2-il)-tetrahidro-pirimidin-2(1H)-ona, 1,3-bis-(4-metil-piridin-2-il)-imidazolidin-2-ona, 1-(5-cloro-1H-benzo-[d]-imidazol-2-il)-3-fenil-imidazolidin-2-ona, o 2-(2-oxo-3-fenil-imidazolidin-1-il)-1H-benzo-[d]-imidazol-5-carbonitrilo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1500CH2009 | 2009-06-26 | ||
| IN2181DE2009 | 2009-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078228A1 true AR078228A1 (es) | 2011-10-26 |
Family
ID=42357251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102237A AR078228A1 (es) | 2009-06-26 | 2010-06-24 | Inhibidores de cyp17 |
Country Status (43)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20171415T4 (hr) | 2009-06-25 | 2023-03-03 | Alkermes Pharma Ireland Limited | Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja |
| US9132105B2 (en) | 2010-08-04 | 2015-09-15 | Pellficure Pharmaceuticals, Inc. | Treatment of prostate carcinoma |
| US8946260B2 (en) | 2010-09-16 | 2015-02-03 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
| CN103298345B (zh) | 2011-01-11 | 2016-12-14 | 诺瓦蒂斯公司 | 组合 |
| WO2012149413A1 (en) * | 2011-04-28 | 2012-11-01 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
| PL2749555T3 (pl) * | 2011-08-26 | 2019-05-31 | Meiji Seika Pharma Co Ltd | Sposób wytwarzania środka do zwalczania szkodników |
| WO2013049263A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| CN102702223A (zh) * | 2012-05-28 | 2012-10-03 | 盛世泰科生物医药技术(苏州)有限公司 | 一种2-溴-4-氯噻吩并[3,2-c]吡啶的制备方法 |
| MX2014014969A (es) | 2012-06-06 | 2015-03-13 | Novartis Ag | Combinacion de un inhibidor de la 17-alfa-hidroxilasa (c17,20-liasa) y un inhibidor especifico de la pi-3k para tratar una enfermedad tumoral. |
| US20160022606A1 (en) | 2013-03-14 | 2016-01-28 | Pellficure Pharmaceuticals Inc. | Novel therapy for prostate carcinoma |
| TW201534586A (zh) * | 2013-06-11 | 2015-09-16 | Orion Corp | 新穎ｃｙｐ１７抑制劑／抗雄激素劑 |
| US9981928B2 (en) | 2013-06-20 | 2018-05-29 | Bayer Cropscience Aktiengesellschaft | Aryl sulfide derivatives and aryl sulfoxide derivatives as acaricides and insecticides |
| EP3718544A1 (en) * | 2013-10-01 | 2020-10-07 | Novartis AG | Combination |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| US10093620B2 (en) | 2014-09-12 | 2018-10-09 | Pellficure Pharmaceuticals, Inc. | Compositions and methods for treatment of prostate carcinoma |
| US9783527B2 (en) * | 2014-09-16 | 2017-10-10 | Abbvie Inc. | Indazole ureas and method of use |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| PE20171067A1 (es) | 2014-10-14 | 2017-07-24 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| HK1247089A1 (zh) | 2015-03-10 | 2018-09-21 | Aduro Biotech, Inc. | 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法 |
| KR20180026774A (ko) | 2015-07-17 | 2018-03-13 | 후지필름 가부시키가이샤 | 질소-함유 헤테로시클릭 화합물 |
| WO2017019894A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| CN114272371A (zh) | 2015-07-29 | 2022-04-05 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| CN108697791B (zh) | 2015-11-03 | 2022-08-23 | 詹森生物科技公司 | 特异性结合pd-1的抗体及其用途 |
| MX2018007423A (es) | 2015-12-17 | 2018-11-09 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas. |
| CN109563126B (zh) * | 2016-06-06 | 2023-06-16 | 马克斯-普朗克科学促进学会 | 蛋白酶体抑制剂 |
| WO2017211818A1 (en) * | 2016-06-06 | 2017-12-14 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Proteasome inhibitors |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| CA3044812A1 (en) | 2016-10-24 | 2018-05-03 | Pellficure Pharmaceuticals Inc. | Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione |
| CN110430878A (zh) | 2016-12-27 | 2019-11-08 | 富士胶片株式会社 | 抗肿瘤剂及溴结构域抑制剂 |
| CN108264509B (zh) * | 2016-12-30 | 2021-05-04 | 复旦大学 | 取代的苯并噻吩并[2，3-c]四氢吡啶衍生物及其制备方法和用途 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| EP3679028A1 (en) * | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydroquinolinones |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| JP7384812B2 (ja) | 2018-03-05 | 2023-11-21 | アルカームス ファーマ アイルランド リミテッド | アリピプラゾール投与戦略 |
| AU2019237329B2 (en) * | 2018-03-22 | 2024-03-28 | Aurigene Discovery Technologies Limited | Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| AU2020327022B2 (en) * | 2019-08-08 | 2025-12-18 | Laekna Limited | Method of treating cancer |
| WO2021053559A1 (en) | 2019-09-18 | 2021-03-25 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| UY39863A (es) * | 2021-07-22 | 2023-02-28 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus |
| US20250092066A1 (en) * | 2022-01-18 | 2025-03-20 | Aurigene Oncology Limited | Substituted bicyclic heterocycles as malt-1 inhibitors |
| CN115304591B (zh) * | 2022-07-08 | 2024-10-01 | 广州中医药大学(广州中医药研究院) | 一种桥环甾体合成酶抑制剂及其制备方法和应用 |
| WO2025190395A2 (en) * | 2024-03-14 | 2025-09-18 | Pharmaengine, Inc. | Mta-cooperative prmt5 inhibitor |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL39283A (en) | 1971-05-03 | 1976-01-30 | Ciba Geigy Ag | Substituted 2-oxo or thioxo-3-(5-nitro-imidazol-2-yl)-tetrahydroimidazoles and their manufacture |
| CH590267A5 (es) * | 1972-10-04 | 1977-07-29 | Ciba Geigy Ag | |
| DE2701794A1 (de) * | 1976-01-21 | 1977-07-28 | Ciba Geigy Ag | Oxigenierte n-aryl-diazacyclen |
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| DE3372965D1 (en) | 1982-07-23 | 1987-09-17 | Ici Plc | Amide derivatives |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| AU606677B2 (en) | 1987-04-22 | 1991-02-14 | Merrell Dow Pharmaceuticals Inc. | 17 beta -(cyclopropylimino) androst-5-EN-3 beta- Ol and related compounds useful as C17-20 lyase inhibitors |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| US4966898A (en) | 1989-08-15 | 1990-10-30 | Merrell Dow Pharmaceuticals Inc. | 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors |
| US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
| DE69227986T2 (de) | 1991-03-01 | 1999-06-17 | Electrostatic Technology, Inc., Branford, Conn. | Pulverbeschichtungsverfahren zur herstellung von leiterplatten und ähnlichen |
| US5145845A (en) | 1991-05-14 | 1992-09-08 | Warner-Lambert Co. | Substituted 2-carboxylindoles having pharmaceutical activity |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| US5457102A (en) | 1994-07-07 | 1995-10-10 | Janssen Pharmaceutica, N.V. | Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives |
| DK0633893T3 (da) | 1992-03-31 | 2000-04-17 | Btg Int Ltd | 17-Substituerede steroider, der er nyttige ved cancerbehandling |
| TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| EP1238986B1 (en) | 1992-10-28 | 2008-06-25 | Genentech, Inc. | Use of Vascular endothelial cell growth factor antagonists |
| US5270329A (en) * | 1992-12-10 | 1993-12-14 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| DE4332168A1 (de) * | 1993-02-22 | 1995-03-23 | Thomae Gmbh Dr K | Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| GB9310635D0 (en) | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| JP3916092B2 (ja) | 1993-09-17 | 2007-05-16 | 杏林製薬株式会社 | イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬 |
| SG49321A1 (en) | 1993-09-30 | 1998-05-18 | British Tech Group | Synthesis of 17-(3-pyridyl) steroids |
| KR960704852A (ko) | 1993-09-30 | 1996-10-09 | 오노다 마사요시 | 아졸 유도체 및 이의 약제학적 조성물 (Azole derivative and pharmaceutical composition thereof) |
| WO1996014090A1 (en) | 1994-11-07 | 1996-05-17 | Janssen Pharmaceutica N.V. | Compositions comprising carbazoles and cyclodextrins |
| JPH08176111A (ja) * | 1994-12-20 | 1996-07-09 | Kyorin Pharmaceut Co Ltd | Ｎ，ｎ′−ジ置換エチレンジアミン誘導体及びそれらを用いたｎ，ｎ′−ジ置換イミダゾリジノン誘導体の製造方法 |
| ES2332984T3 (es) | 1995-03-30 | 2010-02-16 | Pfizer Products Inc. | Derivados de quinazolinas. |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| WO1997000257A1 (en) | 1995-06-14 | 1997-01-03 | Yamanouchi Pharmaceutical Co., Ltd. | Fused imidazole derivatives and medicinal composition thereof |
| ES2172670T3 (es) | 1995-07-06 | 2002-10-01 | Novartis Ag | Pirrolpirimidinas y procedimientos para su preparacion. |
| WO1997008150A1 (en) | 1995-08-22 | 1997-03-06 | The Du Pont Merck Pharmaceutical Company | Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| NZ332119A (en) | 1996-04-12 | 2001-08-31 | Warner Lambert Co | Quinazoline compounds which are irreversible inhibitors of tyrosine kinases |
| CA2254769A1 (en) * | 1996-05-20 | 1997-11-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| BR9709959A (pt) | 1996-06-24 | 2000-05-09 | Pfizer | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas |
| JP2001500851A (ja) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | エポシロンの製造法および製造過程中に得られる中間生産物 |
| AU4141697A (en) | 1996-09-06 | 1998-03-26 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| WO1998010767A2 (en) | 1996-09-13 | 1998-03-19 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| WO1998022461A1 (de) | 1996-11-18 | 1998-05-28 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| RU2203890C2 (ru) | 1997-10-02 | 2003-05-10 | Даиичи Фармасьютикл Компани, Лтд. | Производные дигидронафталина |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| EP1058679B1 (en) | 1998-02-25 | 2005-10-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues therof |
| WO1999054309A1 (en) | 1998-04-23 | 1999-10-28 | Takeda Chemical Industries, Ltd. | Naphthalene derivatives, their production and use |
| CA2339961C (en) | 1998-08-11 | 2009-01-20 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| CN100381566C (zh) | 1998-11-20 | 2008-04-16 | 科森生物科学公司 | 产生环氧噻酮及其衍生物的重组方法和材料 |
| ATE300957T1 (de) | 1998-12-22 | 2005-08-15 | Genentech Inc | Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung |
| AU766081B2 (en) | 1999-03-30 | 2003-10-09 | Novartis Ag | Phthalazine derivatives for treating inflammatory diseases |
| CA2396596A1 (en) | 2000-01-28 | 2001-08-02 | Bristol-Myers Squibb Company | Tetrahydropyrimidone inhibitors of fatty acid binding protein and method |
| JP2002302488A (ja) * | 2000-03-30 | 2002-10-18 | Takeda Chem Ind Ltd | 置換１，３−チアゾール化合物、その製造法および用途 |
| NO312876B1 (no) * | 2000-07-21 | 2002-07-15 | Balans Man As | Regulerbar stol |
| WO2002020493A2 (en) | 2000-09-06 | 2002-03-14 | Chugai Seiyaku Kabushiki Kaisha | A traceless solid-phase synthesis of 2-imidazolones |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| US20040198773A1 (en) | 2001-09-26 | 2004-10-07 | Barry Hart | Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors |
| GB0200283D0 (en) * | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
| ATE548354T1 (de) | 2002-07-24 | 2012-03-15 | Ptc Therapeutics Inc | Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen |
| ATE433968T1 (de) | 2002-09-18 | 2009-07-15 | Pfizer Prod Inc | Imidazolverbindungen als inhibitoren des transformierenden wachstumsfaktors (twf) |
| GB0418900D0 (en) | 2004-08-24 | 2004-09-29 | Btg Int Ltd | Novel salt forms |
| WO2006078698A1 (en) | 2005-01-19 | 2006-07-27 | Cengent Therapeutics, Inc. | 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases |
| CN101155823A (zh) | 2005-03-02 | 2008-04-02 | 马里兰州立大学 | 新的c-17-杂芳基甾族的cyp17抑制剂/抗雄激素物质：其合成，体外生物学活性，药代动力学和抗肿瘤活性 |
| JPWO2006104280A1 (ja) | 2005-03-31 | 2008-09-11 | 武田薬品工業株式会社 | 糖尿病の予防・治療剤 |
| AR060050A1 (es) | 2006-03-21 | 2008-05-21 | Epix Delaware Inc | Compuestos moduladores del receptor de s1p y uso de los mismos |
| AU2007287099A1 (en) | 2006-08-25 | 2008-02-28 | Cougar Biotechnology, Inc. | Methods for treating cancer comprising the administration of a vitamin D compound and an additional therapeutic agent, and compositions containing the same |
| WO2008044700A1 (en) * | 2006-10-11 | 2008-04-17 | Takeda Pharmaceutical Company Limited | GSK-3β INHIBITOR |
| EP2108017A2 (en) | 2007-01-30 | 2009-10-14 | Biogen Idec MA, Inc. | Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists |
| WO2008154382A1 (en) | 2007-06-06 | 2008-12-18 | University Of Maryland, Baltimore | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| CN101084881B (zh) | 2007-06-23 | 2012-08-29 | 淮北辉克药业有限公司 | 靶向速释泡腾制剂及其制备方法 |
| WO2009078992A1 (en) * | 2007-12-17 | 2009-06-25 | Amgen Inc. | Linear tricyclic compounds as p38 kinase inhibitors |
| CA2712897A1 (en) * | 2008-01-30 | 2009-08-06 | Pharmacopeia, Inc. | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
| TW201008930A (en) * | 2008-05-19 | 2010-03-01 | Schering Corp | Heterocyclic compounds as factor IXa inhibitors |
| AU2009262241B2 (en) | 2008-06-25 | 2014-05-22 | Forum Pharmaceuticals Inc. | 1, 2 disubstituted heterocyclic compounds |
| PE20110136A1 (es) | 2008-06-27 | 2011-03-17 | Novartis Ag | Compuestos organicos |
| JP2012505898A (ja) | 2008-10-16 | 2012-03-08 | シェーリング コーポレイション | ピロリジン、ピペリジンおよびピペラジン誘導体ならびにそれらの使用方法 |
| US8431699B2 (en) | 2009-02-27 | 2013-04-30 | Vertichem Corporation | Method for manufacture of 2-oxoimidazolidines |
| AU2010279398A1 (en) | 2009-08-07 | 2012-03-08 | Tokai Pharmaceuticals, Inc. | Treatment of prostate cancer |
| BR112012012167A2 (pt) | 2009-11-13 | 2017-10-03 | Tokai Pharmaceuticals Inc | Metabólitos mamíferos de esteróides |
| WO2011088160A2 (en) | 2010-01-15 | 2011-07-21 | Biomarin Pharmaceutical Inc. | Novel cyp17 inhibitors |
| GB201002563D0 (en) | 2010-02-15 | 2010-03-31 | Cambridge Entpr Ltd | Compounds |
-
2010
- 2010-06-24 KR KR1020127001913A patent/KR101360725B1/ko active Active
- 2010-06-24 SI SI201030633T patent/SI2445903T1/sl unknown
- 2010-06-24 CN CN201080028351.3A patent/CN102803250B/zh active Active
- 2010-06-24 JP JP2012516752A patent/JP5456891B2/ja active Active
- 2010-06-24 RS RS20140323A patent/RS53384B/sr unknown
- 2010-06-24 WO PCT/EP2010/059029 patent/WO2010149755A1/en not_active Ceased
- 2010-06-24 AR ARP100102237A patent/AR078228A1/es unknown
- 2010-06-24 JO JO2010210A patent/JO2892B1/en active
- 2010-06-24 NZ NZ596488A patent/NZ596488A/xx not_active IP Right Cessation
- 2010-06-24 ME MEP-2014-65A patent/ME01886B/me unknown
- 2010-06-24 GE GEAP201012550A patent/GEP20156250B/en unknown
- 2010-06-24 UA UAA201115301A patent/UA105794C2/uk unknown
- 2010-06-24 EA EA201200049A patent/EA021011B1/ru not_active IP Right Cessation
- 2010-06-24 UY UY0001032730A patent/UY32730A/es not_active Application Discontinuation
- 2010-06-24 CA CA2765983A patent/CA2765983C/en active Active
- 2010-06-24 AU AU2010264698A patent/AU2010264698C1/en active Active
- 2010-06-24 MA MA34559A patent/MA33451B1/fr unknown
- 2010-06-24 MX MX2011013771A patent/MX2011013771A/es active IP Right Grant
- 2010-06-24 PE PE2011002130A patent/PE20121048A1/es not_active Application Discontinuation
- 2010-06-24 PT PT107301327T patent/PT2445903E/pt unknown
- 2010-06-24 EP EP10730132.7A patent/EP2445903B1/en active Active
- 2010-06-24 SG SG2011084407A patent/SG176105A1/en unknown
- 2010-06-24 PL PL10730132T patent/PL2445903T3/pl unknown
- 2010-06-24 MY MYPI2011005620A patent/MY155570A/en unknown
- 2010-06-24 BR BRPI1015568A patent/BRPI1015568B8/pt active IP Right Grant
- 2010-06-24 DK DK10730132.7T patent/DK2445903T3/da active
- 2010-06-24 ES ES10730132.7T patent/ES2475945T3/es active Active
- 2010-06-24 HR HRP20140593AT patent/HRP20140593T1/hr unknown
- 2010-06-25 TW TW099120966A patent/TWI492942B/zh not_active IP Right Cessation
- 2010-06-28 US US12/824,845 patent/US8263635B2/en not_active Ceased
-
2011
- 2011-11-15 ZA ZA2011/08373A patent/ZA201108373B/en unknown
- 2011-11-29 TN TNP2011000611A patent/TN2011000611A1/en unknown
- 2011-12-01 IL IL216741A patent/IL216741A/en not_active IP Right Cessation
- 2011-12-19 CU CU2011000235A patent/CU24039B1/es active IP Right Grant
- 2011-12-20 CR CR20110684A patent/CR20110684A/es unknown
- 2011-12-21 DO DO2011000399A patent/DOP2011000399A/es unknown
- 2011-12-21 NI NI201100223A patent/NI201100223A/es unknown
- 2011-12-22 CL CL2011003266A patent/CL2011003266A1/es unknown
- 2011-12-22 HN HN2011003371A patent/HN2011003371A/es unknown
- 2011-12-22 CO CO11177195A patent/CO6480927A2/es active IP Right Grant
-
2012
- 2012-01-26 EC EC2012011625A patent/ECSP12011625A/es unknown
-
2013
- 2013-06-28 US US13/929,901 patent/USRE45173E1/en active Active
-
2014
- 2014-04-21 US US14/257,433 patent/US20140228394A1/en not_active Abandoned
- 2014-06-26 CY CY20141100465T patent/CY1115426T1/el unknown
- 2014-07-10 SM SM201400091T patent/SMT201400091B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078228A1 (es) | Inhibidores de cyp17 | |
| PE20180356A1 (es) | Derivados de etinilo como moduladores del receptor metabotropico del glutamato | |
| PE20181144A1 (es) | Derivados de heteroarilo como inhibidores de parp | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| AR067413A1 (es) | Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| PE20221336A1 (es) | Compuestos triciclicos sustituidos | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| PE20150352A1 (es) | Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona | |
| AR082886A1 (es) | Compuestos y composiciones farmaceuticas que los contienen | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR080688A1 (es) | Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.5]nonano como agonistas o antagonistas inversos de grelina | |
| AR078732A1 (es) | Compuestos heterociclicos fusionados como moduladores del receptor de la orexina | |
| PE20170682A1 (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias | |
| PE20100087A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| AR062125A1 (es) | Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos | |
| SI3009431T1 (en) | 2- (2,4,5-substituted-anilino) pyrimidine derivatives, as EGFR modulators useful for the treatment of cancer | |
| AR109958A1 (es) | Lactamas bicíclicas de piridona y sus métodos de uso | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR085489A1 (es) | Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias | |
| AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
| AR086019A1 (es) | COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS | |
| AR092955A1 (es) | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |